Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Capacity to consent and wish to participate in the study, documented by signing the specific informed consent form (ICF) of the study.~* Age of 18 years or older.~* Pregnancy documented by urine or blood examination or ultrasound.~* Gestational age of 14 to 30 weeks calculated by ultrasound, obstetric examination or date of last menstruation, depending on what is considered to be more exact by the medical investigator.~* HIV infection documented by two serological tests using different methods or analysis of HIV viral load with a positive result.~* No use of antiretroviral drugs at the time of diagnosis of pregnancy (previous prophylaxis and treatment are allowed).~* Intention to continue the treatment of the study for at least 6 weeks after delivery.~Exclusion Criteria:~* History of hypersensitivity to lopinavir or ritonavir.~* Need for the concomitant use of contraindicated drugs in combination with lopinavir/ritonavir.~* Any condition that, in the opinion of the medical researchers, impairs the participation in and fulfillment of the procedures of the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).